Trial Profile
An Open-label, Multi-center, Phase 2 Study of AMG 162 (denosumab) in Subjects with Giant Cell Tumor of Bone
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 23 May 2016
Price :
$35
*
At a glance
- Drugs Denosumab (Primary)
- Indications Bone cancer; Giant cell tumours
- Focus Therapeutic Use
- Sponsors Daiichi Sankyo Company
- 24 Sep 2015 New trial record
- 23 Jul 2015 Results published in the Annals of Oncology.